This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
vaccines: Archive
Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.
PFENegative Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Upwork (UPWK) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
UPWKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Granite Ridge Resources, Inc. (GRNT) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GRNTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Perdoceo Education (PRDO)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PRDOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange
by Zacks Equity Research
J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.
JNJNegative Net Change ANTXPositive Net Change ANVSNegative Net Change KVUENegative Net Change
biotechs consumer-staples medical pharmaceuticals vaccines
U.S. Govt to Urge Citizens to Get New COVID-19 Shots
by Zacks Equity Research
Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.
PFENegative Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
by Zacks Equity Research
Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.
JNJNegative Net Change MRKPositive Net Change PIRSPositive Net Change ETONNegative Net Change
biotechs medical pharmaceuticals vaccines
Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.
PFENegative Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs medical messenger-rna vaccines
Solaris Oilfield Infrastructure, Inc. (SOI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SOIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ARMPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, City Holding (CHCO)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CHCOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, FinWise Bancorp (FINW)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FINWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Acadia Realty Trust (AKR) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AKRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
First Bancorp (FBP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FBPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Popular (BPOP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BPOPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut
by Zacks Equity Research
Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.
JNJNegative Net Change NVOPositive Net Change NVAXPositive Net Change CRBUNegative Net Change
biotechs earnings medical vaccines
4 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Sundeep Ganoria
Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.
NVAXPositive Net Change ARCTNegative Net Change EBSPositive Net Change AXSMPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.
JNJNegative Net Change MRKPositive Net Change MRNAPositive Net Change CRBUNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
AZNNegative Net Change JNJNegative Net Change MRKPositive Net Change MRNAPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
NVOPositive Net Change MRKPositive Net Change MRNAPositive Net Change ACADNegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales
by Zacks Equity Research
AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance.
AZNNegative Net Change JNJNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechs earnings gene-therapy medical pharmaceuticals vaccines
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.
GSKNegative Net Change JNJNegative Net Change ALKSNegative Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Visteon (VC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dana (DAN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DANPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Par Petroleum (PARR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PARRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines